Metsera Inc.'s Lock-Up Period To End on July 30th (NASDAQ:MTSR)

Metsera's (NASDAQ:MTSR - Get Free Report) lock-up period will end on Wednesday, July 30th. Metsera had issued 15,277,778 shares in its IPO on January 31st. The total size of the offering was $275,000,004 based on an initial share price of $18.00. Shares of the company owned by major shareholders and company insiders will be eligible for trade following the end of the lock-up period.

Analysts Set New Price Targets

A number of equities analysts have recently issued reports on MTSR shares. Guggenheim raised their target price on shares of Metsera from $56.00 to $62.00 and gave the stock a "buy" rating in a research report on Tuesday, June 10th. Wells Fargo & Company began coverage on Metsera in a research report on Friday, June 20th. They issued an "overweight" rating and a $65.00 price target on the stock. Five research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company currently has a consensus rating of "Buy" and an average target price of $55.00.

Metsera Trading Up 2.1%

MTSR traded up $0.82 on Friday, hitting $40.47. 1,019,151 shares of the company were exchanged, compared to its average volume of 752,554. Metsera has a fifty-two week low of $12.30 and a fifty-two week high of $47.40. The business has a fifty day moving average price of $31.84.

Metsera (NASDAQ:MTSR - Get Free Report) last released its quarterly earnings data on Monday, May 12th. The company reported ($1.03) earnings per share for the quarter.

Hedge Funds Weigh In On Metsera

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Alphabet Inc. purchased a new stake in Metsera during the 1st quarter worth about $135,059,000. Jennison Associates LLC purchased a new stake in shares of Metsera during the first quarter worth about $9,679,000. Massachusetts Financial Services Co. MA acquired a new position in shares of Metsera in the first quarter valued at approximately $13,111,000. Deutsche Bank AG purchased a new position in shares of Metsera during the first quarter valued at approximately $374,000. Finally, Price T Rowe Associates Inc. MD acquired a new stake in Metsera during the first quarter worth approximately $42,395,000.

Metsera Company Profile

Metsera, Inc is a clinical stage biopharmaceutical company, which engages in the development of a next-generation injectable and oral nutrient stimulated hormone, or NuSH, analog peptides to treat obesity, overweight and related conditions. Its product pipeline includes MET-097i, MET-233, and MET-224o.